FLUDEOXYGLUCOSE
Alzheimer Disease, Early Onset
Columbia UniversitySmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Alzheimer Disease, Early Onset cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sra-333 Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Gonadotropin-Releasing Hormone Nelly Pitteloud | Phase 2/3 | CCC |
Gnrh Nelly Pitteloud | Phase 2/3 | CCC |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Nelly Pitteloud | Phase 2/3 | CCC |
ad04 ADvantage Therapeutics | Phase 2 | CCC |
View all 25 →
Same molecule, other indications
FLUDEOXYGLUCOSE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →